SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is gaining attention, with community members highlighting its recent launch on Phantom Wallet and potential for significant growth. The conversation revolves around 'moon' and 'rocket' references suggesting possible rapid price appreciation. Some users are pointing out potential scam risks.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors closely monitor the Gen AI Summit for potential catalysts, with speculation around new contracts and strategic partnerships driving community interest; analysts have increased price targets, further fueling the bullish sentiment. Discussions also focus on the company's competitive positioning in the AI data market and its potential for expansion into enterprise and government sectors. Despite some concerns about high valuation, the overall tone remains optimistic, as investors eagerly await further developments and Q3 earnings results.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending following FDA approval of their leukemia drug, Revuforj, though a boxed warning regarding potentially fatal side effects tempers initial enthusiasm. The community is debating the impact of the safety label, comparing it to competitor Kura Oncology's profile, and weighing whether the market is overreacting given the drug's efficacy and the unmet need it addresses. Some believe the dip is a buying opportunity, while others worry about potential risks and side effects.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

GBTC is trending as Bitcoin flirts with all-time highs, driving discussion about potential breakouts and future price targets. Community members are closely watching technical indicators and whale activity, anticipating a continued uptrend. Broader market factors, like potential shifts from gold to Bitcoin and the impact of government policies, are also being considered.

Aflac, Inc. is a holding company, which engages in the provision of financial protection services. It operates through the following segments: Aflac Japan and Aflac U.S. The Aflac Japan segment offers life insurance, death benefits, and cash surrender values. The Aflac U.S. segment sells voluntary supplemental insurance products for people who already have major medical or primary insurance coverage. The company was founded by John Amos, Paul Amos and William Amos on November 17, 1955 and is headquartered in Columbus, GA.

Aflac Inc.

Aflac is trending as traders discuss potential options strategies and ROI opportunities, with particular interest in calls expiring in 2025 and 2027. Community members are weighing the stock's technical indicators, buyback program, and analyst ratings, while considering both short-term gains and long-term dividend prospects. Some investors are reacting to recent news, including updated ratings from analysts and the company's cybersecurity incident disclosure.

AABG Token

AABB is trending as investors discuss the potential for a share squeeze and look forward to upcoming news regarding the wallet, dividends, and a potential legal action against market manipulation. Community members express confidence in the company's progress and are accumulating shares while awaiting key catalysts. The rise in gold and silver prices is also fueling optimism for AABB's future.

XDC Network is an enterprise-ready hybrid Blockchain technology company optimized for international trade and finance. The XDC Network is powered by the native coin called XDC. The XDC protocol is architected to support smart contracts, 2000TPS, 2seconds transaction time, KYC to Masternodes (Validator Nodes). The XDC Chain (XinFin Digital Contract) uses XinFin Delegated Proof of Stake (XDPoS), with the intending to create a ‘highly-scalable, secure, permission, and commercial grade’ blockchain network. XinFin mainnet token XDC and also creates an opportunity to utilize the XinFin’s real-world use-cases such as TradeFinex.org, helps small and medium businesses or institutions originate their own financial requirements in a digital, fully structured manner so that they can distribute it to the bank or non-bank funders themselves using a common distribution standard.

XinFin Network

XDC is trending as the community discusses its potential for real-world asset tokenization and adoption in trade finance, with some highlighting its regulatory alignment and institutional partnerships. Despite some frustration over price stagnation, many believe XDC is a sleeping giant poised for significant growth, particularly with upcoming catalysts and infrastructure developments. Conversations also mention potential listings on major exchanges and comparisons to other ISO 20022 compliant cryptocurrencies.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG, a ProShares Short Dow30 ETF, is trending as traders discuss its potential for hedging against a possible market pullback, particularly with the Dow showing signs of volatility. The community highlights call options and celebrates the strong community supporting the Bitcoin-native meme coin, $DOG, with some anticipating major exchange listings and comparing it to early Dogecoin.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to increased interest in AI-driven healthcare solutions, particularly after presenting at the GITEX Global conference in Dubai. The community is focused on the stock's high short interest and potential for a short squeeze, referencing NVIDIA's investment as a positive signal. Some anticipate news or catalysts that could trigger a significant upward move.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with the community debating potential price movements and the impact of broader market factors like interest rate expectations. Discussions also involve technical analysis and long-term growth prospects, with some users expressing excitement and others cautioning about potential pullbacks.  The potential for S&P 500 inclusion and crypto trading are also fueling bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Equity

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer Trinity Capital Inc. Provides $130 Million in...

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Shares of Candel Therapeutics, Inc. (CADL) traded 8% higher on Wednesday morning after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced">granted</a> Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate CAN-2409 for the treatment of a certain kind of prostate cancer.CAN-2409 is being studied for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and was previously granted FDA Fast Track designation for the same indication.RMAT designations are intended to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.Candel’s lead candidate was granted the designation based on positive data from a late-stage trial evaluating the efficacy and safety of the investigational drug plus a prodrug, together with external beam radiation therapy, in newly diagnosed, localized, intermediate-to-high-risk prostate cancer.Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application (BLA) seeking permission to commercialize. The company is looking to submit the application by the end of 2026.RMAT designations offer the company access to mechanisms designed to fast-track BLA review and approval.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_10_27_02_AM_png_786b86992f.webp" alt="CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits " width="628" height="63"><figcaption>CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user opined that the shares are suitable for holding in the mid- to long-term.<stembedurl>https://stocktwits.com/Bowlofpasta/message/616040223</stembedurl>According to data from Koyfin, all three analysts covering CADL rate it a ‘Buy.’ The stock has an average price target of $21.67, implying an upside of over 200% from its current value.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> is down by about 33% this year and by about 30% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/macys-q1-earnings-tops-estimates/ch0okCjRbsh">Macy’s Q1 Earnings Top Estimates, But Company Cuts 2025 Guidance Over Tariff Concerns, Weaker Consumer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy

Best Momentum Stocks to Buy for May 19th

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's  What You Should Know

Shares of Candel Therapeutics, Inc. (CADL) surged nearly 10% on Tuesday afternoon after the company reported upbeat first-quarter (Q1) earnings.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results">reported</a> diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024, and surpassing an estimated loss of $0.35 per share, as per Finchat data.It said the rise in net income was primarily related to the change in the fair value of the company’s warrant liability.While research and development expenses narrowed year-on-year in the quarter, general and administrative expenses rose.The biopharmaceutical company ended the first quarter with cash and cash equivalents of $92.2 million compared to $102.7 million as of Dec. 31, 2024. Candel expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.CEO Paul-Peter Tak said that the company’s primary focus for 2025 remains working toward submitting an application to the U.S. Food and Drug Administration (FDA) for the commercialisation of its investigational immunotherapy candidate and lead asset CAN-2409 for the treatment of prostate cancer. The submission is expected in the fourth quarter of 2026.“We are now focusing on executing strategic preparations for potential commercialization, to ensure that, if approved, CAN-2409 is immediately available to patients with localized prostate cancer,” he said.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel rose within the ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_41_07_PM_png_6a3877db5b.webp" alt="CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CADL/sentiment">CADL stock</a> is down by about 39% this year and 46% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amd-google-uber-stocks-rally-after-committing-to-invest-80-b-in-600b-us-saudi-deal/chi8AJjRbZN">AMD, Google, Uber Stocks Rally After Committing To Invest $80B As Part Of US-Saudi $600B Trade Pact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc